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Abstract: We report a case of 22-year-old primigravida presented to Women’s Hospital – Hamad 
Medical Corporation emergency with severe epigastric pain, nausea, and vomiting. On admission, 
she was dehydrated with remarkably worsening symptoms. Laboratory findings revealed significantly 
elevated liver enzymes with unknown etiology. Her past medical history showed an admission for 
nausea and vomiting 3 weeks previously and she was discharged on antiemetics, and esomeprazole 
for the first time. Due to the predominantly elevated liver enzymes, the clinical pharmacist discussed 
the possibility of esomeprazole-induced adverse effects and suggested to suspend esomeprazole 
based on the evidence from literature review. The liver enzymes showed a substantial improvement 
within days after the discontinuation of the drug; however, a rechallenge was not done since it could 
have adversely affected the mother or the fetus. Using the Naranjo Adverse Drug Reaction Prob-
ability scales, the adverse reaction due to esomeprazole was classified as “probably”.
Keywords: hyperemesis, drug-induced liver injury, esomeprazole, adverse drug reaction, ADR, 
proton pump inhibitor
Introduction
Drug-induced hepatic toxicity is one of the most common causes of liver injury, 
accounting for almost one-half of all the liver failure and mimics all forms of liver 
disease. Approximately >1000 medications have been reported to cause liver disease 
at least one time. However, majority of these liver diseases subside after suspension 
of the drug, while very few of them have been reported to cause a permanent harm. 
The majority of drug-induced hepatic adverse events are unpredictable and are either 
immune-mediated hypersensitivity reactions or idiosyncratic.1,2
Esomeprazole is an S-isomer of omeprazole and is generally considered safe and 
effective to treat acid suppression during pregnancy.3–5 However, US Food and Drug 
Administration classified it as Category C, which explains that animal reproduction 
studies have shown an adverse effect on the fetus and there are no adequate and well-
controlled studies on humans, but potential benefits may warrant use of the drug in 
pregnant women despite potential risks.6
We report a case of probable esomeprazole-induced transient liver injury (elevated 
liver transaminases, i.e., alanine transaminase [ALT] and aspartate transaminase [AST]) 
in a pregnant woman which resolved after discontinuation of the suspected drug. A 
literature search of standard databases (MEDLINE, Embase, and Cumulative Index to 
Nursing and Allied Health Literature) conducted in September 2015 did not identify 
any similar reports in pregnant population.
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Figure 1 Elevated liver enzymes with esomeprazole.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase.
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Impact on practice
Health professionals treating hyperemesis gravidarum or 
gastric refluxes should be aware of potential esomeprazole-
induced liver toxicities.
Liver enzyme levels should be carefully monitored while 
prescribing esomeprazole to a pregnant woman.
Case presentation
No informed consent was required from the patient to pub-
lish this report due to its anonymous nature. This waiver of 
informed consent and all approvals to publish and present 
this case was obtained from the Medical Research Centre at 
Hamad Medical Corporation (HMC).
A 22-year-old primigravida in her first trimester pre-
sented to Women’s Hospital – HMC emergency with acute 
epigastric pain, nausea, and nonbilious vomiting more than 
four times in last 24 hours. Her past medical history revealed 
that 3 weeks previously (considered as Day 0 in Figure 1), 
she was admitted to the hospital and was diagnosed as hyper-
emesis gravidarum and was later discharged on pyridoxine, 
metoclopramide, and esomeprazole. The patient had no 
known diagnosis of liver injury/disease prior to the onset of 
this illness and denied history of any recreational drug use, 
nonprescription, or use of herbal supplements. Prior to cur-
rent admission (Day 1), she was taking esomeprazole 40 mg 
twice daily, metoclopramide suppositories 20 mg twice daily, 
and pyridoxine 40 mg orally once daily and had no history 
of drug allergies or other adverse drug reactions.
At this time, the patient continued to complain of significant 
nausea, vomiting, poor appetite, significant weight loss, and 
darkish yellow urine. On examination, she was dehydrated, no 
signs of ascites or edema, impalpable spleen; however, severe 
tenderness was observed in the epigastric area. Laboratory 
investigation revealed significantly elevated ALT (267 Units/L) 
and AST (137 Units/L; Figure 1). HIV testing was negative. A 
deferential diagnosis was made as Mallory–Weiss tear (diag-
nosed clinically) and hyperemesis gravidarum versus viral/
autoimmune liver disease or drug-induced liver injury (DILI). 
Viral hepatitis screening test and other tests including anti-
smooth muscle antibody, antimitochondria antibody, antinuclear 
antibody, and antiliver kidney microsomal antibodies were done.
This reaction (elevated liver enzymes) was identified by 
the clinical pharmacist who discussed the possibility of an 
esomeprazole-induced adverse effect. The outcome of the 
discussion resulted in discontinuing esomeprazole (Day 5) 
and replacing it with oral pantoprazole 40 mg twice daily. 
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Esomeprazole-induced transient liver injury
This change in therapy had almost immediate impact, with 
liver enzymes having dropped predominantly in successive 
days, without any other intervention. Approximately 3 days 
(Day 7) after stopping esomeprazole, subsequent laboratory 
reports demonstrated that patient’s AST, ALT, and alkaline 
phosphatase were significantly reduced. The patient reported 
a substantial improvement in her activity levels with resolu-
tion of nausea and vomiting and epigastric pain, and she was 
discharged on Day 10. On discharge, she was prescribed 
with pantoprazole 40 mg and metoclopramide suppositories 
20 mg and was asked to follow-up after a week. During her 
subsequent follow-up visit on Day 16, the liver functions 
were found to be normal.
Using the Naranjo Adverse Drug Reaction Probability 
scales, a score of 6 was obtained indicating a “probable” 
adverse reaction due to esomeprazole. The patient was 
instructed never to rechallenge herself with esomeprazole 
and instructed to report it as a medication adverse reaction 
in the future.
Discussion
To our knowledge, this is the first published report of oral 
esomeprazole-induced liver injury in a pregnant patient. 
While the pathophysiology of DILI is poorly understood, 
some of the possible mechanisms for drug-induced hepato-
toxicity include 1) impaired intracellular calcium hemosta-
sis, leading to disassembly of actin fibrils and resulting in 
bulging of cell membrane to cause rupture and cell lysis; 2) 
Drug-induced hepatotoxicity is also caused due to loss of 
villous processes and the disruption of transport pumps, for 
example, MRP3 that prevents the excretion of bilirubin and 
other organic compounds; 3) Sometimes due to stimulation of 
apoptotic pathways by tumor necrosis factor alpha (TNF -a), 
receptor or Fas may trigger the cascade of intercellular 
caspases. Certain drugs are known to cause mitochondrial 
 dysfunction by reducing the ATP production and disturbing 
the respiratory chain enzyme and hence causing hepatic 
toxicity. DILI is known as the most common cause of liver 
injury and main cause of drug withdrawal. It is known that 
>50% of all acute liver failures and ~10% of all acute hepatitis 
cases are due to drugs.2,7,8 There are two main types of hepatic 
toxicity, one is the immune response to the drug trigger and 
the other is direct action of the drug itself. Esomeprazole 
induces drug injury and is more of a direct toxicity because 
when the drug is withdrawn, the pathologic findings were 
resolved. Authors have also assumed the role of immune 
system in the current case because of the delayed nature of 
the reaction and resolution. Although, direct destruction of 
liver epithelium by drugs has been reported previously with 
acetaminophen, it might also occur in other medications. 
This type of injury may result in altered salt homeostasis, 
mitochondrial dysfunction, and cell death. Rechallenge here 
is not recommended since a recurrent injury may be more 
severe than the first episode and might adversely affect the 
fetus too.
A search on UK MHRA and MedEffect Canada and a 
literature review of standard databases (MEDLINE, Embase, 
and Cumulative Index to Nursing and Allied Health Litera-
ture) conducted in September 2015 did not identify any simi-
lar reports in pregnant women. Rare but previously reported 
esomeprazole-induced liver injury has occurred in male 
population or with other underlining conditions; however, no 
such reports were reported in pregnant population till date.
Capitain et al9 reported liver toxicity in a patient receiving 
chemotherapy, for breast cancer, after single administration 
of esomeprazole. Upon withdrawal of esomeprazole, liver 
enzymes returned to normal even after the continuation 
of the chemotherapy. In another two studies, omeprazole 
was the main cause of DILI reported.10,11 A similar case of 
transient hepatic injury that resolved soon after esomepra-
zole was discontinued following a negative work up against 
viral infection or autoimmune disease, the dose-dependent 
elevation of ALT and AST, and return of liver enzymes to 
normal after switching to another proton pump inhibitor (PPI) 
(omeprazole) was also reported.
Esomeprazole is the S-isomer of omeprazole. Both 
esomeprazole and pantoprazole are metabolized through 
CYP 450 enzymes, and they are known enzyme inhibitors 
for their own metabolism. Therefore, higher areas under the 
curve (AUC) are attained with continuous use. Once metabo-
lized, hydroxy, 5-O-desmethyl, and sulfone metabolites are 
formed. However, the formation of hydroxy metabolite is 
slower, and the formation of the other two metabolites is more 
rapid in esomeprazole compared to pantoprazole.12 Hence, 
the formation of metabolites might explain the toxic effect 
on the liver and support the direct liver injury over immune 
reaction. Pantoprazole has not shown a similar metabolism 
and does not inhibit its metabolism. The diversity in meta-
bolic pathways may explain in part the different consequence 
on liver functions between PPIs.12,13
Conclusion
A case of probable esomeprazole-induced transient liver 
injury in pregnant women was reported. It is important for 
health care professionals to be aware of this rare but signifi-
cantly harm producing event in pregnancy. This case has been 
reported to Medication Safety Office and Drug Information 
services – Women’s Hospital Medication safety office and 
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Drug Information services. Authors recommend that future 
cases of suspected esomeprazole-induced hepatotoxicity 
should be reported and efforts to delineate the mechanism 
of injury should be undertaken.
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